Proactive Investors - Run By Investors For Investors

Athersys CEO highlights progress of lead therapy MultiStem to help stroke patients

Athersys Inc (NASDAQ: ATHX) CEO Dr. Gil Van Bokkelen together with patient and stroke victim Sharon Thomas joined Proactive Investors in New York to discuss how MultiStem, Athersys' lead therapy, is progressing through the drug-development cycle.

Thomas was treated with MultiStem when the drug was in Phase 2. It has since progressed to Phase 3 with FDA Fast Track designation. What's more, a separate clinical program evaluating MultiStem cell therapy for the treatment of Acute Respiratory Distress Syndrome has received Fast Track designation.

 
View full ATHX profile View Profile

Athersys Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use